ACTG A5001 - LONGITUDINAL LINKED RANDOMIZED TRIALS (ALLRT) PROTOCOL
ACTG A5001 - 纵向连锁随机试验 (ALLRT) 方案
基本信息
- 批准号:7719419
- 负责人:
- 金额:$ 4.22万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-04-01 至 2008-05-31
- 项目状态:已结题
- 来源:
- 关键词:AIDS clinical trial groupBloodClinicalClinical TrialsComputer Retrieval of Information on Scientific Projects DatabaseDataData AnalysesEnd PointEnrollmentEvaluationFundingGrantImmunologicsIndividualInstitutionLinkMeta-AnalysisMonitorOutcomeParentsProtocols documentationPurposeRandomizedRandomized Controlled Clinical TrialsResearchResearch PersonnelResourcesScheduleSeriesSourceTimeUnited States National Institutes of HealthVisitWeekantiretroviral therapycohortfollow-upprospective
项目摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
The ALLRT protocol is a planned series of prospective meta-analyses and cross-protocol analyses of data to be collected from an established longitudinal and cross-sectional cohort of HIV-infected individuals who have been prospectively randomized into approved parent ACTG clinical trials, and who have agreed to be followed long-term for the purpose of evaluating clinical, virologic, immunologic, and pharmacologic outcomes associated with long-term treatment with potent antiretroviral therapies. All subjects initially entered into the ALLRT protocol will be participating concurrently in a parent ACTG study or have completed participation in a parent clinical trial within the previous 8 weeks. Subjects entered into the ALLRT protocol may have additional blood and data collected for clinical, virologic, immunologic, and pharmacologic evaluations. Long-term follow-up will continue within the context of parent ACTG protocols until those studies close or an endpoint is reached. For subjects entered into the ALLRT protocol who reach an endpoint on their parent protocol or their parent protocol participation otherwise ends, and for whom participation in an alternative ACTG randomized trial is not immediately available or feasible, long-term follow-up with clinical, virologic, immunologic, and pharmacologic monitoring will continue according to the schedule outlined in the ALLRT protocol. Subjects may subsequently enroll in additional randomized ACTG clinical trials over time and still maintain participation in the ALLRT protocol, with study visits timed to coincide as nearly as possible.
这个子项目是众多研究子项目之一
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
THOMAS A CAMPBELL其他文献
THOMAS A CAMPBELL的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('THOMAS A CAMPBELL', 18)}}的其他基金
ACTG A5211-SAFETY AND EFFICACY OF SCH 417690 IN HIV-INF, TRTMNT-EXP SUBJCTS
ACTG A5211-SCH 417690 在 HIV-INF、TRTMNT-EXP 受试者中的安全性和有效性
- 批准号:
7719470 - 财政年份:2008
- 资助金额:
$ 4.22万 - 项目类别:
ACTG 362-METAB,CARDIOVAS&NEUROLCOMPLICA'S IN SUBJ'S W/PAST CD4 CELL
ACTG 362-METAB,卡迪瓦斯
- 批准号:
7719416 - 财政年份:2008
- 资助金额:
$ 4.22万 - 项目类别:
ACTG A5095 -PROTEASE INHIBITOR-SPARING REGIMENS FOR THE INITIAL TREATMENT OF HIV
ACTG A5095 - HIV 初始治疗的蛋白酶抑制剂保留方案
- 批准号:
7719426 - 财政年份:2008
- 资助金额:
$ 4.22万 - 项目类别:
EVALOF EFFICACY OF ONCE/DAY PROTEASE INHBTR& ONCE/DAY NONNUCLEOSIDE REVERSE
每日一次蛋白酶 INHBTR 的功效评估
- 批准号:
7719467 - 财政年份:2008
- 资助金额:
$ 4.22万 - 项目类别:
MEASURE CLEARANCE OF REPLICATION-COMPETENT HIV-1 IN RESTING MEMORY CD4+ CELLS
测量静息记忆 CD4 细胞中复制能力的 HIV-1 清除率
- 批准号:
7719441 - 财政年份:2008
- 资助金额:
$ 4.22万 - 项目类别:
ACTG A5164(V 20)-ANTIRETROVIRAL THERAPY FOR HIV-INFECTED ADULTS W/ACUTE OIS
ACTG A5164(V 20)-针对感染 HIV 并患有急性 OIS 的成人的抗逆转录病毒治疗
- 批准号:
7719463 - 财政年份:2008
- 资助金额:
$ 4.22万 - 项目类别:
CEREBRAL & NEUROCOGNITIVE FNCTN IN HIV-INFECTED PRSNS W/ADVNCD HRT DISZ ON HAART
大脑
- 批准号:
7719523 - 财政年份:2008
- 资助金额:
$ 4.22万 - 项目类别:
ACTG A5146:IMPACT OF THERAPEUTIC DRUG MONITORING (TDM) ON VIROLOGIC RESPONSE
ACTG A5146:治疗药物监测 (TDM) 对病毒学反应的影响
- 批准号:
7719430 - 财政年份:2008
- 资助金额:
$ 4.22万 - 项目类别:
ACTG A5202 (VS 10): TRIAL OF OPEN-LABEL EFAVIRENZ OR ATAZANAVIR WITH RITONAVIR
ACTG A5202(VS 10):开放标签依非韦伦或阿扎那韦与利托那韦的试验
- 批准号:
7719505 - 财政年份:2008
- 资助金额:
$ 4.22万 - 项目类别:
ACTG A5030-VALGANCICLOVIR PRE-EMPTIVE THERAPY FOR CYTOMEGALOVIRUS (CMV) VIREMIA
ACTG A5030-缬更昔洛韦预防巨细胞病毒 (CMV) 病毒血症
- 批准号:
7719423 - 财政年份:2008
- 资助金额:
$ 4.22万 - 项目类别:
相似海外基金
Examination of the psychophysiological mechanism of facial skin blood flow in emotion processing and its clinical application
情绪处理中面部皮肤血流的心理生理机制探讨及其临床应用
- 批准号:
22KJ2717 - 财政年份:2023
- 资助金额:
$ 4.22万 - 项目类别:
Grant-in-Aid for JSPS Fellows
CLINICAL VERIFICATION AND VALIDATION OF A WEARABLE NEAR-INFRARED BLOOD ALCOHOL CONTENT MONITOR.
可穿戴式近红外血液酒精含量监测仪的临床验证和确认。
- 批准号:
10954103 - 财政年份:2023
- 资助金额:
$ 4.22万 - 项目类别:
Diagnostic aptamer reagents to develop multi-analyte blood test for pre-clinical, mild and moderate Alzheimer's disease
诊断适体试剂用于开发针对临床前、轻度和中度阿尔茨海默病的多分析物血液检测
- 批准号:
10597840 - 财政年份:2023
- 资助金额:
$ 4.22万 - 项目类别:
Dynamics and clinical significance of minimal residual disease in peripheral blood collected from high-risk neuroblastoma patients.
高危神经母细胞瘤患者外周血微小残留病的动态及临床意义。
- 批准号:
23K14977 - 财政年份:2023
- 资助金额:
$ 4.22万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Longitudinal Blood-based Transcriptomic Changes in AD: Relation to Clinical and Biomarker Data
AD 中基于血液的纵向转录组变化:与临床和生物标志物数据的关系
- 批准号:
10555728 - 财政年份:2023
- 资助金额:
$ 4.22万 - 项目类别:
Leveraging remote blood pressure monitoring and interpretable machine learning to improve clinical workflows for hypertensive disorders of pregnancy
利用远程血压监测和可解释的机器学习来改善妊娠期高血压疾病的临床工作流程
- 批准号:
10822625 - 财政年份:2023
- 资助金额:
$ 4.22万 - 项目类别:
Validation of biomarkers predicting clinical outcomes of umbilical cord blood transplantation
预测脐带血移植临床结果的生物标志物的验证
- 批准号:
MR/W029669/1 - 财政年份:2023
- 资助金额:
$ 4.22万 - 项目类别:
Research Grant
Adherence to Clinical Practice Guidelines for Screening and Management of Pediatric High Blood Pressure within a Massachusetts Safety-Net Health Care System
遵守马萨诸塞州安全网医疗保健系统内儿童高血压筛查和管理的临床实践指南
- 批准号:
10464844 - 财政年份:2022
- 资助金额:
$ 4.22万 - 项目类别:
Blood & Marrow Clinical Trials Network- Hutchinson Center as Core Clinical Site
血
- 批准号:
10430215 - 财政年份:2022
- 资助金额:
$ 4.22万 - 项目类别:
Blood & Marrow Clinical Trials Network- Hutchinson Center as Core Clinical Site
血
- 批准号:
10673065 - 财政年份:2022
- 资助金额:
$ 4.22万 - 项目类别: